Literature DB >> 21943874

Impact of wound blush as an angiographic end point of endovascular therapy for patients with critical limb ischemia.

Makoto Utsunomiya1, Masato Nakamura, Mami Nakanishi, Takurou Takagi, Hidehiko Hara, Kiyoshi Onishi, Tetsuro Yamada, Kaoru Sugi.   

Abstract

OBJECTIVES: Several reports have been published of the acceptable patency and limb salvage rates after infrapopliteal interventions for the treatment of critical limb ischemia (CLI). However, the optimal angiographic end point of endovascular therapy (EVT) remains unclear. This study assessed the relationship between the appearance of wound blush as an angiographic end point and the limb salvage rate in patients with CLI.
METHODS: "Wound blush" was defined as contrast opacification of the vessels around the wound in digital subtraction angiograms obtained immediately after EVT through the catheter introduced into the popliteal artery. We analyzed the data of 77 consecutive patients (93 limbs) with ischemic ulcerations, classified as Rutherford category 5 or 6, who underwent EVT without bypass surgery. Patients were divided into two groups depending on whether wound blush was seen in the angiogram obtained immediately after the procedure. The freedom from amputation rate was compared between the two groups.
RESULTS: The overall limb salvage rate was 81.7%. The limb salvage rate was significantly higher in the wound blush-positive group than in the wound blush-negative group and remained so for at least 3 years after the EVT (96.4% vs 56.8%, P < .001).
CONCLUSIONS: Presence of wound blush after EVT is associated with higher skin perfusion pressure, both of which are associated with higher rates of limb salvage. Wound blush as an angiographic end point in EVT may be a novel predictor of limb salvage in patients with CLI.
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21943874     DOI: 10.1016/j.jvs.2011.08.001

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

Review 1.  On the Cutting Edge: Wound Care for the Endovascular Specialist.

Authors:  Brandon Olivieri; Timothy E Yates; Sofia Vianna; Omosalewa Adenikinju; Robert E Beasley; Jon Houseworth
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

2.  Clinical outcome of angiosome-oriented infrapopliteal percutaneous transluminal angioplasty for isolated infrapopliteal lesions in patients with critical limb ischemia.

Authors:  Eui-Yong Jeon; Young Kwon Cho; Dae Young Yoon; Dae Jung Kim; Jeong Joo Woo
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

Review 3.  Treatment of infrapopliteal critical limb ischemia in 2013: the wound perfusion approach.

Authors:  Matthew C Bunte; Mehdi H Shishehbor
Journal:  Curr Cardiol Rep       Date:  2013-06       Impact factor: 2.931

4.  Skin ulcer due to hemodialysis access-induced distal ischemia treated with arteriovenous fistula banding and endovascular therapy.

Authors:  Susumu Odajima; Takumi Inoue; Tomoyo Hamana; Ryota Masaki; Wataru Fujimoto; Koji Kuroda; Yutaka Hatani; Masamichi Iwasaki; Hiroshi Okamoto; Masanori Okuda; Takatoshi Hayashi
Journal:  J Cardiol Cases       Date:  2019-08-18

5.  Endovascular revascularization for patients with critical limb ischemia: impact on wound healing and long term clinical results in 189 limbs.

Authors:  Jae-Ik Bae; Je Hwan Won; Seung Hwan Han; Sang Hyun Lim; You Sun Hong; Jae-Young Kim; Ji Dae Kim; Jun-Su Kim
Journal:  Korean J Radiol       Date:  2013-05-02       Impact factor: 3.500

6.  IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial.

Authors:  Thomas Zeller; Iris Baumgartner; Dierk Scheinert; Marianne Brodmann; Marc Bosiers; Antonio Micari; Patrick Peeters; Frank Vermassen; Mario Landini
Journal:  Trials       Date:  2014-02-19       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.